Option chain shows key data for Runway Growth Finance Corp. - 7.50% Notes due 2027's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Runway Growth Finance Corp. - 7.50% Notes due 2027.

Runway Growth Finance Corp. - 7.50% Notes due 2027 (NASDAQ:RWAYL) Stock, Option Chain

Runway Growth Finance Corp. - 7.50% Notes due 2027

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 36 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 41% bullish and 44%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $468,617, and 26 are calls, for a total amount of $1,742,517.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1040.0 for Eli Lilly over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 484.97, with a total volume reaching 1,651.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1040.0, throughout the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739380523_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$42.75</td>
<td>$42.7</td>
<td>$42.75</td>
<td>$960.00</td>
<td>$384.7K</td>
<td>67</td>
<td align="right">102</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$23.7</td>
<td>$22.45</td>
<td>$22.45</td>
<td>$875.00</td>
<td>$134.7K</td>
<td>18</td>
<td align="right">66</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$109.95</td>
<td>$109.0</td>
<td>$109.0</td>
<td>$900.00</td>
<td>$109.0K</td>
<td>1.0K</td>
<td align="right">11</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$20.65</td>
<td>$19.75</td>
<td>$20.65</td>
<td>$875.00</td>
<td>$103.2K</td>
<td>18</td>
<td align="right">116</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$115.3</td>
<td>$113.55</td>
<td>$115.3</td>
<td>$840.00</td>
<td>$92.2K</td>
<td>145</td>
<td align="right">8</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,031,908, the price of LLY is up by 1.05%, reaching $874.11.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1190. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1038. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Behind the Scenes of Eli Lilly's Latest Options Trends

WIIM

ELMD

Electromed shares are trading following a Q2 EPS beat.

WISA

WiSA Technologies shares are trading higher after the company announced it signed an interoperability license agreement with Dolby to accelerate its wireless audio integration for Android and Linux A/V platforms.

Macro Economic Events

News

Economics

Federal Reserve

Fed Chair Powell Says It's Past Time For Congress To Work On Sustainability Of Fiscal Path; Successful Programs To Get Back On Right Fiscal Path Take A Long Time; It's Not Something You Can Get To Overnight; What Needs To Be Done On Fiscal Situation Must Be Done On A Bipartisan Basis

Trading Ideas

AREN

The Arena Group Shares Resume Trade

ALGS

Aligos Therapeutics shares are trading lower after the company announced a $105 million private placement financing round.

Philip Morris International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), one of the largest tobacco companies in the world, has undergone a dramatic transformation over the past few years. As cigarette smoking continues its decades-long decline, PMI has aggressively expanded into smokeless alternatives, with Zyn &#8211; its flagship nicotine pouch brand &#8211; emerging as a major driver of growth.
Zyn's rapid adoption in the U.S. market has played a key role in PMI's resurgence. Earlier this year, the Food and Drug Administration (FDA) <a href="https://www.benzinga.com/25/01/43054519/zyn-nicotine-pouches-receive-fda-marketing-approval">authorized</a> 20 Zyn products for sale, <a href="https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-20-zyn-nicotine-pouch-products-after-extensive-scientific-review">determining</a> that these pouches contain "substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products." This regulatory green light reinforced Zyn's positioning as a lower-risk alternative to traditional tobacco products.
PMI's $16 billion acquisition of Swedish Match, the original manufacturer of Zyn, in 2022 has proven to be a strategic coup. The company reported shipping 238 million cans of Zyn in the U.S. that year, with projections indicating that this number will more than double in 2024. According to <a href="https://www.cnbc.com/2025/01/29/-how-zyn-helped-philip-morris-international-make-a-comeback-.html?&amp;qsearchterm=zyn">CNBC</a>, PMI has committed over $832 million to expand Zyn's production capacity, including new manufacturing plants in Aurora, Colorado and Owensboro, Kentucky.
This shift aligns with PMI's <a href="https://www.pmi.com/our-progress/pmi-announces-ambition-to-become-a-more-than-two-thirds-majority-smoke-free-company-by-2030">broader corporate strategy</a>: by 2030, the company aims for two-thirds of its revenue to come from smoke-free products, with an eventual goal of moving entirely away from cigarettes. As Goldman Sachs senior analyst Bonnie Herzog told CNBC, "The beauty of this transformation is that they're actually generating faster top-line and faster profitability given the pivot to these businesses."
With Zyn's meteoric rise, PMI has demonstrated that nicotine pouches are more than just a passing trend. They represent a scalable, profitable and consumer-friendly alternative to traditional tobacco products. The question now is: can a similar shift happen in the cannabis industry?
<h3 class="wp-block-heading">From Nicotine To Nootropics: Pouches Are Just Getting Started</h3>
While Zyn has reshaped the nicotine industry, its success is part of a broader shift in how consumers approach smokeless and discreet consumption. Pouches, as a delivery system, are gaining traction across multiple categories, including cannabinoids, caffeine and nootropics. This trend suggests that the appeal of pouches extends far beyond nicotine replacement, opening the door for new product innovations.
Nick Kenny, lead advisor at KBS Strategic Advisory, has worked closely with major tobacco companies exploring these adjacent markets. He points out that Zyn's success has fueled renewed interest in pouches as a delivery method for other substances.
"The widespread adoption of oral nicotine pouches by regulators and adult consumers has spurned renewed interest in the category as a delivery method for cannabinoids," Kenny told <a href="https://www.benzinga.com/cannabis">Benzinga</a> in an exclusive interview. "Big Tobacco [companies] are consistently looking to diversify and enhance their portfolio of offerings, and where they can leverage existing technology to differentiate, such as in the case of pouches, it's a natural adjacency to take advantage of."
Beyond nicotine, companies are expanding into new bioactive substances that fit well within the pouch format. Cannadips, a California-based company specializing in smokeless, spit-free pouches, has pioneered THC and CBD-infused alternatives to traditional oral tobacco. Co-founder Case Mandel has been at the forefront of this shift, developing pouches infused with THC, CBD, caffeine and nootropics.
"We participate in all those different categories (&#8230;) we have brands in all the different verticals," Mandel told Benzinga. "Pouches are becoming an acceptable way to consume many different things."
The appeal of pouches is rooted in their smoke-free, discreet and fast-acting nature. Unlike traditional edibles or tinctures, which must pass through the digestive system, pouches deliver active ingredients through oral absorption, leading to a quicker onset of effects. This efficiency has made them particularly attractive for consumers looking for functional products, whether for focus, energy, relaxation or mood enhancement.
Caffeine pouches have already started to take off, following a similar trajectory to nicotine pouches. Mandel notes that the market has grown significantly, with his company seeing success in partnerships like Upperdeckys, a high-dose caffeine pouch brand that has gained popularity through influencer marketing.
"We have the highest-dose caffeine pouch product on the market," Mandel said. "Every pouch is almost like an energy drink."
Meanwhile, nootropic pouches infused with compounds aimed at enhancing cognitive function have also started to gain momentum. Mandel's company has developed nootropic pouches under the Rebel brand, leveraging ingredients like Alpha-GPC and Cognizin to cater to consumers looking for performance-enhancing alternatives.
"We see that the new age of consumers want healthier products, they want to know where their ingredients are from and they want cutting-edge delivery systems," Mandel said.
With consumer behavior shifting toward discreet, functional and efficient consumption, pouches are proving to be a format with applications far beyond nicotine. The question now is whether cannabis pouches can follow the same path, carving out a substantial market segment like Zyn did in the nicotine space.
<h3 class="wp-block-heading">Can THC Pouches Follow In Zyn's Footsteps?</h3>
While nicotine and functional ingredient pouches have gained mainstream traction, cannabis-infused pouches remain a niche product. Forbes' Will Yakowicz recently <a href="https://www.forbes.com/sites/willyakowicz/2025/01/31/zyn-with-weed-cannadips-pouch-craze-hits-the-cannabis-industry/">reported</a> on the rise of THC-infused pouches, spotlighting companies like Cannadips and Juana Dips that are leading the charge in this emerging category. These companies are working to establish THC pouches as a viable segment within the cannabis industry, but the path to success is far from straightforward.
While Mandel sees major potential, he acknowledges the significant barriers to scaling THC pouches. "We believe THC pouches are going to be a big market in the future," he said. "But due to the incredibly high capital expenditure costs of pouching machines and intellectual property –and this really poorly fragmented state-by-state regulatory model due to lack of federal reform– it's been very hard for us or anyone else to get significant traction in the THC pouch space."
Unlike nicotine pouches, which can be sold nationwide in convenience stores, THC-infused pouches are limited by the patchwork of U.S. cannabis laws. Without federal legalization, each state enforces its own licensing and distribution rules, creating barriers to scaling production and streamlining sales.
Without centralized production and wider distribution, THC pouches won't easily compete with dominant cannabis formats like flower and vapes.
"At some point, we, as well as others, will be able to have a factory in one location, provide product to the country and get it for a price that consumers can afford and can build into their daily routine versus like a novelty," Mandel said.
Price is another major factor. Cannabis pouches are significantly more expensive than nicotine pouches, making it difficult to drive widespread adoption. While a can of nicotine pouches typically costs around $6, THC pouches can be three to four times more expensive due to taxes, compliance costs and limited production scalability.
"When consumers see a circular can, especially if they use Rogue or any of these products, they expect the product to be the same price or close to it," Mandel said. "No one&#8217;s going to switch from a $6 product to a $30 product and use it at the same frequency. It's just really hard."
For THC pouches to reach mainstream consumers, Mandel argues that the industry will need some level of federal reform to reduce costs and streamline production.
"Really, in my opinion, it&#8217;s going to have to be about commoditization," he said. "Until we can normalize the price of a THC pouch to be at least close to a nicotine pouch, it will be hard for it to be anything more than a novelty product that people use occasionally rather than incorporating into their daily routine."
Despite these challenges, companies like Cannadips are focusing on regions with strong smokeless tobacco traditions to drive early adoption. The company has launched in Arkansas, Missouri and Kentucky, among others, where dip products are already popular, in an effort to establish pouches as a daily-use product rather than a novelty.
"We&#8217;re looking at areas of strength where we can put our attention to and really show that this isn't just a novelty product," Mandel said. "This is a product that people are building into their daily lives."
For THC pouches to reach mass-market success, pricing, regulations and consumer awareness will need to improve. If those barriers are addressed, they could become a major category within the cannabis industry. The next question is whether Big Tobacco and large cannabis operators will step in to accelerate growth—or if THC pouches will remain a niche product.
<h3 class="wp-block-heading">Who Will Fund The Rise Of Cannabis Pouches?</h3>
As cannabis pouches attempt to carve out a foothold in the market, the key question remains: Will large-scale industry players, whether Big Tobacco or major cannabis operators, step in to accelerate their adoption?
Nick Kenny believes tobacco companies are closely monitoring the category but will only invest if they see clear market potential and broad distribution opportunities. "Big Tobacco [companies] have the desire and ability to make the category successful. However, they will only do so if they can deliver a product that can differentiate in experience and attain widespread distribution," he said.
Kenny also noted that consumer adoption and regulatory barriers will both play critical roles in determining the success of THC pouches. Unlike nicotine pouches, which benefit from nationwide distribution, THC pouches face restrictions due to fragmented state-by-state cannabis laws, making it difficult for companies to scale efficiently.
Despite these challenges, Case Mandel sees long-term potential. "We created the category. We&#8217;ve been doing this now for nine years," he said. "We&#8217;ve solved a lot of the issues when it comes to delivery of cannabinoids."
Still, affordability remains a major hurdle. Without economies of scale, THC pouches are significantly more expensive than nicotine pouches, limiting mass adoption.
"Recreational cannabis is really expensive, and it's really expensive compared to traditional [illicit] markets in a lot of states," Mandel said.
One potential avenue for wider availability is hemp-derived THC pouches, which fall under the 2018 Farm Bill. However, Mandel points out that regulations on THC content per pouch make them less competitive than edibles, vapes and drinks. "Because a pouch is only 500 milligrams, you&#8217;re looking at a milligram and a half of THC per pouch," he explained.
Rather than trying to force national expansion too early, Mandel's strategy is to focus on regions with strong smokeless tobacco traditions, where dip users may be more likely to embrace the format.
"We&#8217;re kind of looking at areas of strength where we can put our attention to and really show, ‘Hey, this isn't just a novelty product. This is a product that people are building into their daily life,'" he said.
The future of cannabis pouches will depend on major industry investment, evolving regulations, and consumer demand. If a major player—either in cannabis or tobacco—commits to mass production and distribution, the market could scale quickly.
For now, THC pouches remain a niche product, but the potential is there. If a dominant player enters the space, cannabis pouches could redefine consumption—just as Zyn did with nicotine.
Lead image via Shutterstock

Cannabis

Health Care

Exclusives

Interview

Zyn Changed Nicotine Forever - Are Cannabis Pouches The Next Big Thing?

Department store chain Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) has disclosed its succession&nbsp;plan for Chief Financial Officer role.
David Kennerley, who is currently the senior vice president and CFO for PepsiCo Inc Europe, will step into the role of senior vice president and CFO at Kroger beginning April 3, succeeding Todd Foley.
Kennerley will officially join the company on March 10, with Foley continuing as interim CFO until the end of Kroger&#8217;s fiscal year 2024.
In 2021, he was appointed group vice president and corporate controller; in 2024, he took on the role of interim CFO.
Foley will remain part of the senior leadership team, helping with the transition until the close of Kroger&#8217;s first quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43651110/starbucks-faces-legal-action-over-alleged-discriminatory-hiring-practices" rel="noreferrer noopener">&#8216;Racism Has No Place in Missouri&#8217;: State Attorney General Sues Starbucks Over Hiring Policies</a>
On the other hand, Kennerley has had an extensive career at PepsiCo, joining the company in 2001. He has held several important roles, including serving as CFO for PepsiCo Europe.
&#8220;Consistent with Kroger&#8217;s history of thoughtful succession planning, David and Todd will transition seamlessly to ensure Kroger continues to deliver on its go-to-market strategy, providing access to fresh, affordable food for families across America and, by doing so, creating long term shareholder value,&#8221; said&nbsp;Chairman and CEO Rodney McMullen.
In December, competitor Albertsons Companies Inc called off its planned merger with Kroger and took legal action against the grocery giant, claiming that Kroger breached the merger agreement by not doing enough to obtain the <a target="_blank" href="https://www.benzinga.com/news/legal/24/12/42444582/albertsons-puts-an-end-to-merger-deal-sues-kroger-following-court-ruling-we-believe-strongly-in-the-merits-of-our-case" rel="noreferrer noopener">necessary regulatory approval</a>.
Price Action: KR shares are trading higher by 0.70% at $65.51 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43656323/burger-king-parent-restaurant-brands-posts-q4-beat-on-robust-demand" target="_blank" rel="noreferrer noopener">Burger King Parent Restaurant Brands Q4: Earnings Beat, 26% Sales Jump, Popeyes Comps Dip And More</a></li>
</ul>
Photo via Shutterstock.

Equities

Management

General

Grocery Giant Kroger Picks PepsiCo Executive David Kennerley As Finance Head

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions shares are trading higher. The stock may be moving on continued strength after the company released on Monday a shareholder letter highlighting its growth for 2024 and strategy for 2025.

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 200 points on Wednesday.
The Dow traded down 0.47% to 44,383.04 while the NASDAQ fell 0.01% to 19,642.01. The S&amp;P 500 also fell, dropping, 0.27% to 6,052.27.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Health care shares rose by 0.2% on Wednesday.
In trading on Wednesday, real estate shares dipped by 1.1%.
Top Headline
Crude oil inventories gained by 4.07 million barrels in the week ended Feb. 7, compared to market estimates of a 3 million build, the EIA said.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares shot up 148% to $0.5761 after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.</li>
<li>Shares of Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>)got a boost, surging 100% to $1.3150 after the company announced an option-to-license collaboration agreement with AbbVie to develop novel tumor-activated antibody-based immunotherapies.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) shares were also up, gaining 29% to $86.89 after the company reported better-than-expected fourth-quarter financial results and issued FY25 revenue guidance above estimates. Multiple analysts upgraded the stock following the report.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares dropped 51% to $9.72 after the company filed a complaint against Kpler Holding, alleging Kpler failed to close on the acquisition of Spire&#8217;s maritime business. The company said given the expected delay, it intends to seek additional equity or debt financing.</li>
<li>Shares of Atomera Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) were down 41% to $5.13 following a fourth-quarter EPS miss and a year-over-year decline in sales results.</li>
<li>Similarweb Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NASDAQ">SMWB</a>) was down, falling 36% to $10.71 after the company missed quarterly earnings estimates.</li>
</ul>
Commodities In commodity news, oil traded down 2.4% to $71.56 while gold traded down 0.5% at $2,916.80.
Silver traded up 0.6% to $32.530 on Wednesday, while copper rose 0.6% to $4.6295.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 fell 0.02%, Germany's DAX 40 rose 0.25% and France's CAC 40 rose 0.03%. Spain's IBEX 35 Index rose 0.99%, while London's FTSE 100 rose 0.15%.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 gaining 0.42%, China's Shanghai Composite Index rising 0.85%, Hong Kong's Hang Seng Index jumping 2.64% and India's BSE Sensex falling 0.16%.
Economics
<ul>
<li>U.S. mortgage applications increased by 2.3% from the previous week during the first week of February, following a 2.2% rise from the earlier week.</li>
<li>The headline Consumer Price Index rose to 3% year-over-year in data released Wednesday, up 0.1 percentage points compared to December and above median economist forecasts of 2.9%, as tracked by TradingEconomics.</li>
<li>Crude oil inventories gained by 4.07 million barrels in the week ended Feb. 7, compared to market estimates of a 3 million build, the EIA said.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43655780/how-to-earn-500-a-month-from-cisco-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Cisco Stock Ahead Of Q2 Earnings</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

ATOM

SMWB

SPIR

TIVC

UPST

Crude Oil Down Over 2%; Upstart Shares Jump Following Earnings

Fed Chair Powell Says Not Sure How Federal Govt Move To Bring Workers Back To Office Will Affect Productivity; There Are Benefits From Work From Home; Have Not Had Any Intrusion From Doge, No Calls On That; Fed's Books Are Audited; Government Accountability Office Is Free To Work On Every Area Except Monetary Policy, Which They Don't Audit

Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) will be reporting its second-quarter earnings on Wednesday. Wall Street expects 91 cents in EPS and $13.87 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=CSCO" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 24.88% over the past year, 5.63% year-to-date.
<h2 class="wp-block-heading">Cisco Positioning Itself At The Heart Of AI Action</h2>
Cisco is gearing up for its earnings report with a wave of AI-driven innovations that could give its stock a turbocharged jolt. The tech giant recently launched its new smart switches featuring intelligent networking silicon and embedded data processing units (DPUs), poised to redefine AI data center designs. 
But that's not all — Cisco is empowering service providers to rethink their networks to better handle the avalanche of AI data and traffic, unlocking new monetization opportunities in the process.
Partnering with Mistral AI, Cisco has also rolled out an AI Renewals Agent to simplify the renewal proposal process, a key milestone in its ongoing Customer Experience (CX) evolution. 
As AI becomes the backbone of the next-gen internet, Cisco seems to be positioning itself at the heart of the action — now investors will be watching closely to see how these innovations translate into dollars when the company reports earnings.
Let&#8217;s look at what the charts indicate for Cisco stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/02/43655780/how-to-earn-500-a-month-from-cisco-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Cisco Stock Ahead Of Q2 Earnings</a>
<h2 class="wp-block-heading">Cisco Stock Moderately Bullish Ahead Of Q2 Earnings</h2>
Cisco stock is exhibiting a moderately bullish trend, though slight selling pressure is emerging. The stock is trading above key moving averages, signaling sustained upward momentum. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12113301/Screenshot-2025-02-12-at-8.17.08-PM.png" alt="" class="wp-image-779127" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12113301/Screenshot-2025-02-12-at-8.17.08-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12113301/Screenshot-2025-02-12-at-8.17.08-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021225&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
With Cisco stock at $61.75, it is positioned above the 20-day simple moving average of $61.14 and its 50-day simple moving average (SMA) of $59.86 — both indicating a bullish trend. Additionally, the stock remains well above its 200-day SMA of $52.65, reinforcing long-term strength. However, the eight-day SMA at $62.06 lies above the stock reflecting some selling pressure.
The Moving Average Convergence Divergence (MACD) indicator stands at 0.77, further supporting a bullish outlook. However, the Relative Strength Index (RSI) of 57.02 suggests that is Cisco stock keeps rising, it could be approaching overbought territory, potentially leading to near-term consolidation or a pullback. 
Investors should monitor whether the stock maintains support at shorter-term moving averages to confirm the continuation of its bullish momentum.
<h2 class="wp-block-heading">Cisco Analysts See 8% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/CSCO/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Cisco stock stands at a Buy currently with a price target of $59.50. Citigroup and Morgan Stanley&#8217;s latest ratings suggest an 8.01% upside for Cisco, with a $66.67 average target.
Price Action: Cisco stock was trading at $62.49 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43651497/us-stocks-set-for-a-cautious-start-ahead-of-inflation-data-expert-says-strong-bull-markets-tend-to-roar-back-to-life-after-corrections">US Stocks Set For A Cautious Start Ahead Of Inflation Data: Expert Says &#8216;Strong Bull Markets Tend To Roar Back To Life After Corrections&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

CSCO

Cisco AI Push Sets The Stage For Q2 Earnings: Will Investors Buy In?

INMB

Inmune Bio shares are trading higher after the company announced the completion of the third and highest dose cohort of its Phase 1 portion of the INKmune trial in prostate cancer.

<h3>Gainers</h3>
<ul>
<li>Fangdd Network Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) stock moved upwards by 19.3% to $0.68 during Wednesday's pre-market session. The company's market cap stands at $21.6 million. </li>
<li>Haoxi Health Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) shares increased by 12.27% to $2.05. The company's market cap stands at $5.7 million. </li>
<li>Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) stock rose 9.82% to $1.9. The market value of their outstanding shares is at $946.1 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Able View Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABLV#NASDAQ">ABLV</a>) shares increased by 8.49% to $1.15. The company's market cap stands at $48.1 million. </li>
<li>Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) shares increased by 6.78% to $6.82. The market value of their outstanding shares is at $761.1 million. </li>
<li>Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) shares rose 5.88% to $1.26. The market value of their outstanding shares is at $47.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PodcastOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODC#NASDAQ">PODC</a>) stock fell 17.4% to $1.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $44.8 million. The company's, Q3 earnings came out today. </li>
<li>Society Pass (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) stock fell 17.11% to $4.75. The market value of their outstanding shares is at $17.3 million. </li>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) stock fell 15.55% to $0.08. The market value of their outstanding shares is at $18.9 million. </li>
<li>36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) shares decreased by 9.36% to $4.36. The market value of their outstanding shares is at $170.0 million. </li>
<li>Kuke Music Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KUKE#NYSE">KUKE</a>) shares decreased by 8.7% to $0.4. The market value of their outstanding shares is at $18.3 million. </li>
<li>Emerald Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) shares decreased by 8.66% to $4.01. The company's market cap stands at $813.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABLV

ANGI

BHAT

KRKR

KUKE

PODC

SOPA

STGW

12 Communication Services Stocks Moving In Wednesday's Pre-Market Session

ESOA

Energy Services of America shares are trading higher. The stock may be moving on continued strength after reporting a Q1 revenue beat on Monday.

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) reported worse-than-expected fourth-quarter sales <a href="https://www.benzinga.com/quote/ARVN/earnings">results on Tuesday</a>.
Arvinas reported quarterly losses of 63 cents per share which beat the analyst consensus estimate of a loss of 87 cents per share. The company reported quarterly sales of $59.20 million which missed the analyst consensus estimate of $65.28 million.
&#8220;We made significant progress across our pipeline in 2024, all of which we believe supports our mission to improve the lives of patients with debilitating and life-threatening diseases,&#8221; said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. &#8220;Looking ahead, we are on the cusp of a number of firsts, including results from VERITAC-2, the first ever Phase 3 clinical trial of a PROTAC. In addition, we plan to present the first-in-human data for our most advanced neuroscience program, ARV-102, which we believe will highlight the potential value our PROTAC degraders can offer to patients with neurodegenerative diseases. In the coming months, we look forward to sharing additional updates emerging from our pipeline and PROTAC platform.&#8221;
Arvinas shares gained 1.4% to trade at $17.92 on Wednesday.
These analysts made changes to their price targets on Arvinas following earnings announcement.
<ul>
<li>Stifel analyst Bradley Canino maintained Arvinas with a Buy and lowered the price target from $63 to $51.</li>
<li>BMO Capital analyst Etzer Darout reiterated Arvinas with an Outperform and cut the price target from $88 to $82.</li>
<li>Oppenheimer analyst Matthew Biegler maintained the stock with an Outperform and raised the price target from $40 to $45.</li>
</ul>
Considering buying ARVN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="480" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12120247/image-2-35-1024x480.png" alt="" class="wp-image-779243" style="width:542px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12120247/image-2-35-1024x480.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12120247/image-2-35-300x140.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12120247/image-2-35-768x360.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12120247/image-2-35.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43660222/snowflake-to-rally-around-9-here-are-10-top-analyst-forecasts-for-wednesday">Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Price Target

Analyst Ratings

ARVN

These Analysts Revise Their Forecasts On Arvinas After Q4 Results

John Jarratt Reprises His Role as Mick Taylor, the Crocodile Dundee of Serial Killers!
LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Cineverse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNVS#NASDAQ">CNVS</a>), a next-generation entertainment studio, and Bloody Disgusting, its horror division, have announced today the acquisition of Wolf Creek: Legacy, the third film of the incredibly popular slasher franchise. The announcement was made ahead of the European Film Market (EFM). Filming begins this year with an anticipated theatrical release in the fall of 2026.

CNVS

Cineverse Acquires North American Rights To Wolf Creek: Legacy; Filming Begins This Year With An Anticipated Theatrical Release In The Fall Of 2026.

Cognizant's solution accelerator, powered by Elektrobit's Adaptive AUTOSAR solution, is designed to meet increasing customer demands by accelerating the development cycle for Software-Defined Vehicles
TEANECK, N.J., Feb. 12, 2025 &nbsp;/PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4361168-1&amp;h=3433384680&amp;u=https%3A%2F%2Fwww.cognizant.com%2Fus%2Fen&amp;a=Cognizant">Cognizant</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>)&nbsp;today announced a new collaboration with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4361168-1&amp;h=1896671070&amp;u=https%3A%2F%2Fwww.elektrobit.com%2F&amp;a=Elektrobit">Elektrobit</a>, an award-winning automotive software company, to integrate Elektrobit's Software Development Kit (SDK) for <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4361168-1&amp;h=928912169&amp;u=https%3A%2F%2Fwww.elektrobit.com%2Fproducts%2Fecu%2Feb-corbos%2Fadaptivecore%2F&amp;a=EB+corbos+AdaptiveCore">EB corbos AdaptiveCore</a>&nbsp;into Cognizant's software-defined vehicle (SDV) solution accelerator. This enhanced accelerator, featuring Elektrobit's proven Adaptive AUTOSAR solution, aims to help original equipment manufacturers (OEMs) and Tier 1 suppliers create scalable, flexible, and cost-efficient SDV architectures. The goal is to meet customer demands by speeding up the development cycle.

CTSH

Cognizant And Elektrobit Collaborate To Accelerate Development Of Software-Defined Vehicles

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/02/2025-02-12_08h40_26.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Hotter Inflation</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-hotter-inflation-spy-mc-02122025">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (SPY) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>The chart shows that the stock market was in the micro resistance zone prior to the release of inflation data.</li>
<li>The chart shows that as of this writing after the release of the Consumer Price Index (CPI) data the stock market fell below the low band of the micro resistance zone.</li>
<li>The chart shows that the stock market has made several attempts to break above the micro resistance zone over a period of time.&nbsp; Prudent investors need to note that in spite of extreme bullishness and aggressive buying by the momo crowd, so far, the stock market has failed to break above the micro resistance zone.&nbsp; This indicates that the momo crowd's aggressive buying is meeting selling from other investors.&nbsp;&nbsp;</li>
<li>CPI came hotter than expected.&nbsp; Here are the details:
<ul>
<li>Headline CPI came at 0.5% vs. 0.3% consensus.</li>
<li>Core CPI came at 0.4% vs. 0.3% consensus.</li>
</ul>
</li>
<li>As a reader of The Arora Report, hotter inflation is not a surprise to you.&nbsp; We have been sharing our analysis with you for a while that inflation is likely to be stickier than the Fed and stock market believe. The Arora Report call has kept you ahead of the curve.</li>
<li>Today, Powell will continue his testimony before Congress.&nbsp; Here are the key points from his testimony yesterday:
<ul>
<li>The Fed is not in a rush to make changes because the economy is "in a pretty good place."</li>
<li>If inflation does not improve and the economy is solid, the Fed will hold.</li>
<li>If inflation quickly declines or there is surprise weakness in the labor market, the Fed will cut interest rates.</li>
<li>The neutral rate has increased compared to pre-pandemic.</li>
<li>The reason longer term rates are high is "not particularly closely related to Fed policy." Investor concerns of inflation risks and rising budget deficits could keep longer term rates at higher levels.</li>
</ul>
</li>
<li>The stock market has gotten used to Powell coming to its rescue.  In The Arora Report analysis, this time, Powell is unlikely to come to the stock market's rescue.  Investors need to remember that in December 2018, Powell was doing the right thing by raising interest rates, and the stock market fell because the stock market was used to Powell coming to its rescue but that did not happen. Then, Powell cut interest rates; the stock market had a rip-roaring rally.  Could a repeat of 2018 &#8211; 2019 happen again? Trump is already on the record saying that interest rates should be lower.  This dynamic is taken into account in the protection band.  Please see the "Protection Band And What To Do Now" section below. </li>
<li>The consensus in the stock market is that Trump's tariffs will raise inflation.  Inflation is already higher than consensus.  Prudent investors should note that The Arora Report call is more nuanced.  The Arora Report call is that tariffs can be implemented in a way that, with the exception of a one time increase in inflation, can have a beneficial impact on the U.S. economy and stock market.  Of course, there is no way to know how Trump will implement tariffs.  This uncertainty is also taken into account in the protection band.  </li>
<li>As we have been sharing with you, earnings are the single largest determinant of the stock market in the long term.&nbsp; So far, there is a positive and a negative in earnings.&nbsp;&nbsp;
<ul>
<li>On the positive side, earnings could rise to 12.5% vs. 7.3% expected prior to the start of earnings season.&nbsp; This is significantly above the average of 5.5% since 2022.&nbsp;&nbsp;</li>
<li>On the negative side, only 44% of S&amp;P 500 companies beat operating margin estimates.&nbsp; This is the lowest number since 2022.&nbsp;</li>
<li>The positive and negative of earnings is also taken into account in the protection band.&nbsp;&nbsp;</li>
</ul>
</li>
<li>Producer Price Index (PPI) and initial jobless claims will be released tomorrow at 8:30am ET.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Tesla Inc (TSLA).
In the early trade, money flows are negative in Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), Microsoft Corp (MSFT), and NVIDIA Corp (NVDA).
In the early trade, money flows are negative in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is seeing selling on CPI data.  The Arora Report call is bitcoin is not a hedge but a speculative asset.  Note that The Arora Report call is contrary to what bitcoin bulls want investors to believe.  
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Hot CPI Ahead Of Trump's Tariffs; Powell Not Coming To The Stock Market's Rescue

Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) is facing a dip in its share price on Wednesday, but the company remains <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43652739/carvana-customer-survey-reveals-preferences-of-car-buyers-driving-rapid-growth-of-used-ev-category" rel="noreferrer noopener">a key player in the used electric vehicle market.</a>
Carvana today released its EV Trends Report, shedding light on the growing adoption of used EVs.
The report shows that Carvana&#8217;s EV sales mix leads the used vehicle market as a whole, with 5.7% of its sales coming from EVs in 2024, compared to just 1.3% for the overall used car market.
The primary driver behind this surge in EV interest is the appeal of saving both time and money at the pump, Carvana said in the report.
Vehicle style and performance are also important factors, especially as more EV models become available.
Notably, 80% of EV owners prefer charging at home, with 86% of them driving less than 50 miles daily, making public charging infrastructure less of a necessity, Carvana noted in its report.
Also Read: <a target="_blank" href="https://www.benzinga.com/top-stories/25/02/43433458/yieldmax-rolls-out-new-etf-for-investors-to-tap-into-carvanas-rally-and-generate-income" rel="noreferrer noopener">YieldMax Rolls Out New ETF For Investors To Tap Into Carvana&#8217;s Rally And Generate Income</a>
In addition to its focus on EVs, Carvana is <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/43627318/whats-going-on-with-carvana-stock-today-3" rel="noreferrer noopener">enhancing its operational capabilities as well.</a>
The company announced the integration of its Inspection and Reconditioning Center into the ADESA Indianapolis wholesale auction site.
This &#8220;Megasite&#8221; will combine digital and in-lane auction services with reconditioning, boosting production capacity.
It will also create 200 new jobs in the Indianapolis area, further solidifying Carvana&#8217;s presence in the automotive market.
Price Action: CVNA shares are trading lower by 2% to $265.74 at last check Wednesday.
Photo via Shutterstock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43660298/inflation-spike-sparks-dollar-rally-yields-jump-while-bitcoin-stocks-slide-as-interest-rate-cut-doubts-grow" target="_blank" rel="noreferrer noopener">Inflation Spike Sparks Dollar Rally: Yields Jump, Bitcoin And Stocks Slide As Interest Rate Cut Doubts Grow</a></li>
</ul>

CVNA

What's Going On With Carvana Stock Today?

7.50% NT REDEEM 28/07/2027 USD 25 - 78163D209

Comments

Runway Growth Finance Corp. - 7.50% Notes due 2027

Runway Growth Finance Corp. - 7.50% Notes due 2027 (RWAYL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga